Industry Perspectives

Flare Therapeutics adopts Simplicis Ledger to modernize compound management

By adopting Simplicis Ledger, Flare Therapeutics replaces manual "human-babysitting" of data with automation-ready infrastructure to scale life sciences R&D.
Written byFlare Therapeutics
| 1 min read
A computer being used for management

credit: istock.com/Khanchit Khirisutchalual

Register for free to listen to this article
Listen with Speechify
0:00
1:00

CAMBRIDGE, MA, 2nd March, 2026 - Simplicis, a provider of modern sample and inventory management software for life sciences, today announced that Flare Therapeutics has selected Simplicis Ledger as its primary compound and inventory management platform. The partnership marks a strategic shift for Flare Tx, moving away from fragile, person-dependent workflows toward a resilient, automated foundation for drug discovery.

As biotech teams remain lean, many organizations face "operational fragility”, where critical scientific data relies on a single individual or a web of manual workarounds. Flare Therapeutics recognized this bottleneck and chose Ledger to bridge the gap between physical inventory and digital automation.

“We reached a point where our system required more human babysitting and workarounds than I could reliably provide without help,” said Caitlin O'Brien, Compound Management Lead at Flare Therapeutics. “As the primary compound manager in the company, I needed infrastructure we could actually trust. Ledger gives us that, allowing us to scale without increasing headcount or overhead.”

Breaking the Cycle of "Offline" Data Management

Prior to this implementation, Flare Tx’s workflows, including assay-ready plate production and acoustic dispensing required significant manual oversight and custom IT workarounds. These "offline" processes created operational risks and hindered cross-training.

By implementing Ledger and Ledger Acoustic, Flare Tx has achieved:

  • End-to-End Transparency: Real-time alignment between inventory state and assay execution.
  • Automation-Ready Workflows: Seamless integration with acoustic dispensing platforms, removing the need for manual file handling.
  • Operational Continuity: A unified system that allows for predictable workflow management and easier team-wide adoption.

“Flare Tx’s move reflects a broader biotech trend: the shift from brittle, workaround-driven systems to 'Scientific Infrastructure' that supports velocity,” said James Craven, Chief Commercial Officer at Simplicis. “Ledger was designed to remove the hidden friction between inventory, automation, and people.”

For more information on how Simplicis is modernizing R&D infrastructure, visit www.simplicis.com

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue